Abstract
Osteoporosis, as a skeletal disorder characterized by gradually reduced bone mineral density, is a severe threat to millions of postmenopausal women. MicroRNAs (miRNAs) are important post-transcriptional factors and play an important role in bone degeneration such as osteoporosis and other bone-related diseases. Here we showed that the expression of miR-29b in bone tissue and bone marrow stromal cells (BMSCs) of Ovx mice is descend and overexpression of miR-29b could partially rescued osteogenic differentiation and bone formation ability of Ovx-BMSCs in vitro and in vivo, respectively. Our studies indicated that miR-29b plays an important role in regulating BMSCs osteogenic differentiation and could contribute to osteoporosis therapy.
Highlights
Osteoporosis, the most common bone remodeling disease, is characterized by a systemic impairment of bone mass and microarchitecture and increases the fracture risk of the patient [1]
The expression of alkaline phosphatase (ALP) and OCN in bone tissue and bone marrow stromal cells (BMSCs) of Ovx mice group was significantly decreased compared with Sham mice group. miR-29b, had previously been demonstrated that play a role in osteogenic differentiation, exhibited decreased expression in Ovx mice group than in Sham mice group
The expression of ALP and OCN were quantified in the groups including Sham-BMSCs, Ovx-BMSCs, and Ovx-BMSCs transfected with miR-NC and miR-29b
Summary
Osteoporosis, the most common bone remodeling disease, is characterized by a systemic impairment of bone mass and microarchitecture and increases the fracture risk of the patient [1]. The osteoporotic fracture often causes further severe disability and premature mortality in the aging population due to impaired bone healing abilty [2,3]. Among the extensive treatment approaches currently used in clinics for treating osteoporosis, most of them are focusing on antiresorptive agents, which exert their therapeutic effect by slowing down the bone resorption rate. Bone-anabolic agents including parathyroid hormone (PTH) and and PTH-related peptide (PTHrP) synthetic analogues such as teriparatide and abaloparatide have been used to increased bone formation and reduces bone fracture risk [6,7,8]. Continuous treatment with PTH may cause bone resorption. It is necessary to develop a novel anabolic therapeutic strategy to enhance bone formation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
